Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatm… Read more
Biodexa Pharmaceticals (BDRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.289x
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has a cash flow conversion efficiency ratio of -0.289x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.30 Million) by net assets ($11.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biodexa Pharmaceticals - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Biodexa Pharmaceticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biodexa Pharmaceticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodexa Pharmaceticals ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rennova Health Inc
PINK:RNVA
|
-0.008x |
|
Sesa SpA
STU:1S3
|
0.029x |
|
VISTEON (VS51.SG)
STU:VS51
|
0.077x |
|
Ansal Properties & Infrastructure Limited
NSE:ANSALAPI
|
-0.110x |
|
Coca-Cola Femsa SAB de CV
STU:CFSL
|
0.081x |
|
Suncliff Inc
PINK:SCLF
|
N/A |
|
Uniserve Communications Corporation
PINK:USSHF
|
-0.065x |
|
SHAREHOLD VAL BET N (SVE.SG)
STU:SVE
|
N/A |
Annual Cash Flow Conversion Efficiency for Biodexa Pharmaceticals (2012–2024)
The table below shows the annual cash flow conversion efficiency of Biodexa Pharmaceticals from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.32 Million | $-12.26 Million | -1.473x | -0.97% |
| 2023-12-31 | $4.68 Million | $-6.83 Million | -1.459x | +34.54% |
| 2022-12-31 | $3.16 Million | $-7.05 Million | -2.229x | -287.79% |
| 2021-12-31 | $10.45 Million | $-6.01 Million | -0.575x | +58.48% |
| 2020-12-31 | $6.72 Million | $-9.30 Million | -1.384x | -317.29% |
| 2019-12-31 | $19.56 Million | $-6.49 Million | -0.332x | +58.25% |
| 2018-12-31 | $16.92 Million | $-13.45 Million | -0.795x | -112.75% |
| 2017-12-31 | $34.68 Million | $-12.95 Million | -0.374x | -30.52% |
| 2016-12-31 | $45.72 Million | $-13.09 Million | -0.286x | -8.03% |
| 2015-12-31 | $46.89 Million | $-12.42 Million | -0.265x | -103.91% |
| 2014-12-31 | $41.99 Million | $-5.46 Million | -0.130x | +97.77% |
| 2013-12-31 | $760.00K | $-4.44 Million | -5.837x | -1023.99% |
| 2012-12-31 | $-5.09 Million | $-3.22 Million | 0.632x | -- |